Strong Phase II Resminostat Data Send 4SC Shooting Up
Shares in 4SC AG surged more than 38 percent last week on news that its histone deacetylase (HDAC) inhibitor resminostat hit the primary endpoint of a Phase II trial in advanced hepatocellular carcinoma (HCC).